Receptor Tyrosine Kinases: Volume 147

ISBN-13: 9780128201428 / Angielski / Twarda / 2020 / 312 str.

Paul B. Fisher; Rakesh Kumar

Spis treści

Contributions from:Yosef Yarden, Ph.D., Weizmann Institute of Science, ISRAELRakesh Kumar, Ph.D., Rajiv Gandhi Center for Biotechnology, INDIAPaul Fisher, M.D., Ph.D., Virginia Commonwealth University, School of Medicine, USAMark Moasser, M.D., University of California San Francisco, USA William J. Muller, Ph.D., McGill University, CANADA Ravi Salgia, M.D., Ph.D., City of Hope's Comprehensive Cancer Center, USARenata Pasqualini, Ph.D., Rutgers NJ School of Medicine, USAFernanda Staquicini, Ph.D., Rutgers NJ School of Medicine, USAM. Radhakrishna Pillai, Ph.D., Rajiv Gandhi Center for Biotechnology, INDIAMien-Chie Hung, Ph.D., China Medical University, TAIWANE. Prem Reddy, Ph.D., Mount Sanai School of Medicine, USADoug Yee, M.D., Masonic Cancer Center University of Minnesota, USANandini Verma, Ph.D., Advanced Centre for Treatment, Research and Education in Cancer, Mumbai, INDIA Masakazu Toi, M.D., Ph.D., Kyoto University School of Medicine, JAPANLouis Chow, M.D., UNIMED Medical Institute, Hong Kong, CHINALuis Marques da Costa, M.D., Ph.D., University of Lisbon School of Medicine, PORTUGAL

O autorze

Rakesh Kumar acquired qualifications of Environment Science and Engineering from IIT Bombay in 1987. He then pursued work on developing technologies for automobile pollution control, which also led to a Ph.D.in Environment Engineering. Dr. Kumar's experience includes a wide range of environment science and engineering field, such as: Air Pollution Control and Management, Water and Wastewater Treatment, Hazardous & Municipal Waste Management, Environmental Impact Assessment and Environmental Audit and Climate Change. Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy ("theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).